Lilly Unveils Historic $3.5 Billion Manufacturing Investment in Pennsylvania for Next-Gen Weight-Loss Medicines

Eli Lilly and Company

Eli Lilly and Company has announced a historic $3.5 billion investment to establish a state-of-the-art manufacturing campus in Fogelsville, Pennsylvania. As the largest life sciences project in the Commonwealth’s history, this facility will be dedicated to producing next-generation injectable medicines, including the investigational triple hormone receptor agonist retatrutide. The project is set to create 850 high-value jobs and solidify the Lehigh Valley as a premier global hub for pharmaceutical innovation and domestic supply chain resilience.

Eli Lilly to Invest $3 Billion in New Netherlands Facility to Boost Oral Medicine Production

Eli Lilly and Company

Eli Lilly has announced a $3 billion investment to build a new, state-of-the-art manufacturing facility in Katwijk, Netherlands. Located in the Leiden Bio Science Park, the advanced plant will significantly expand the company’s capacity for its growing portfolio of oral medicines, including the oral GLP-1 drug orforglipron.

AbbVie Invests $70 Million to Expand Biologics Manufacturing and R&D Hub in Massachusetts

AbbVie

AbbVie has broken ground on a $70 million expansion of its Bioresearch Center in Worcester, MA, a key part of its $10 billion U.S. investment plan. The project will add new manufacturing suites and labs to increase domestic production of complex biologic medicines for immunology and oncology, creating new jobs and bringing key manufacturing capabilities from Europe to the United States.